[go: up one dir, main page]

MX2013010999A - Metodos de diagnostico y tratamiento utilizando una genoteca de ligandos. - Google Patents

Metodos de diagnostico y tratamiento utilizando una genoteca de ligandos.

Info

Publication number
MX2013010999A
MX2013010999A MX2013010999A MX2013010999A MX2013010999A MX 2013010999 A MX2013010999 A MX 2013010999A MX 2013010999 A MX2013010999 A MX 2013010999A MX 2013010999 A MX2013010999 A MX 2013010999A MX 2013010999 A MX2013010999 A MX 2013010999A
Authority
MX
Mexico
Prior art keywords
drug
treatment
methods
genoteca
ligandos
Prior art date
Application number
MX2013010999A
Other languages
English (en)
Other versions
MX351228B (es
Inventor
Muralidhar Reddy Moola
Jessica Schilke
Original Assignee
Opko Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Pharmaceuticals Llc filed Critical Opko Pharmaceuticals Llc
Publication of MX2013010999A publication Critical patent/MX2013010999A/es
Publication of MX351228B publication Critical patent/MX351228B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B20/00—Methods specially adapted for identifying library members
    • C40B20/08—Direct analysis of the library members per se by physical methods, e.g. spectroscopy
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B60/00—Apparatus specially adapted for use in combinatorial chemistry or with libraries
    • C40B60/12—Apparatus specially adapted for use in combinatorial chemistry or with libraries for screening libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/575—
    • G01N33/57525—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La presente invención se refiere a métodos de diagnóstico y tratamiento que utilizan una genoteca de ligandos. Específicamente, la invención se refiere a la utilización de una genoteca de ligandos para diagnosticar o detectar una respuesta inducida por fármaco, incluyendo una reacción adversa al fármaco, efectos secundarios, resistencia al fármaco, y eficacia terapéutica. La invención se refiere además a la identificación de biomarcadores asociados con una respuesta inducida por fármaco y a la proporción de un tratamiento médico personalizado.
MX2013010999A 2011-03-24 2012-03-23 Metodos de diagnostico y tratamiento utilizando una genoteca de ligandos. MX351228B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161467256P 2011-03-24 2011-03-24
US201161491717P 2011-05-31 2011-05-31
US201261583881P 2012-01-06 2012-01-06
PCT/US2012/030223 WO2012129457A2 (en) 2011-03-24 2012-03-23 Diagnostic and treatment methods using a ligand library

Publications (2)

Publication Number Publication Date
MX2013010999A true MX2013010999A (es) 2014-03-27
MX351228B MX351228B (es) 2017-09-06

Family

ID=46880042

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013011000A MX2013011000A (es) 2011-03-24 2012-03-22 Descubrimiento de biomarcador en fluido biologico complejo usando genotecas basadas en microesferao particula y kits de diagnostico y terapeuticos.
MX2013010999A MX351228B (es) 2011-03-24 2012-03-23 Metodos de diagnostico y tratamiento utilizando una genoteca de ligandos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013011000A MX2013011000A (es) 2011-03-24 2012-03-22 Descubrimiento de biomarcador en fluido biologico complejo usando genotecas basadas en microesferao particula y kits de diagnostico y terapeuticos.

Country Status (13)

Country Link
US (2) US20120269799A1 (es)
EP (2) EP2688911B1 (es)
JP (2) JP6153921B2 (es)
KR (2) KR20140027174A (es)
CN (2) CN103748270B (es)
AU (2) AU2012230880B2 (es)
BR (2) BR112013024453A2 (es)
CL (2) CL2013002731A1 (es)
CO (2) CO6870029A2 (es)
EA (2) EA032582B1 (es)
MX (2) MX2013011000A (es)
TW (2) TWI630389B (es)
WO (2) WO2012129423A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014019501A1 (zh) * 2012-08-03 2014-02-06 天津工业大学 一种具有锂同位素分离效应的苯并冠醚接枝聚合物及其制备方法
WO2015169973A2 (de) * 2014-05-09 2015-11-12 Protagen Ag Markersequenzen zur diagnose und stratifizierung von systemische sklerose patienten
US10849875B2 (en) 2015-07-23 2020-12-01 University Of Houston System Cancer specific lipid targeted peptidomimetics
CN108347916B (zh) 2015-10-14 2022-02-08 先时迈纳米生物科技股份有限公司 一种减少冰晶形成的组合物及其方法
WO2017156319A1 (en) * 2016-03-09 2017-09-14 Mike-Ann, Llc Peptoid affinity ligands
CN109641935A (zh) * 2016-03-25 2019-04-16 莫拉利达尔·瑞迪·穆拉 组合合成和生物标志物开发
CN106854233B (zh) * 2017-03-03 2020-07-17 国家纳米科学中心 一种类肽及其制备方法和应用
WO2023014666A1 (en) * 2021-08-04 2023-02-09 University Of Houston System Vimentin targeted peptoids for early diagnosis and treatment of cancer

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834318A (en) * 1995-05-10 1998-11-10 Bayer Corporation Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
US20040241759A1 (en) * 1997-06-16 2004-12-02 Eileen Tozer High throughput screening of libraries
US6344330B1 (en) 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
WO2000009464A1 (en) 1998-08-17 2000-02-24 Phylos, Inc. Identification of compound-protein interactions using libraries of protein-nucleic acid fusion molecules
US6329510B1 (en) * 1999-01-29 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-CCR1 antibodies and methods of use therefor
AU2065801A (en) * 1999-12-06 2001-06-12 Panacea Pharmaceuticals, Llc Passive desensitization
US7153682B2 (en) 2000-06-05 2006-12-26 Chiron Corporation Microarrays on mirrored substrates for performing proteomic analyses
US7083945B1 (en) * 2000-10-27 2006-08-01 The Board Of Regents Of The University Of Texas System Isolation of binding proteins with high affinity to ligands
EP1364212B1 (en) 2001-03-02 2011-02-02 GPC Biotech AG Three hybrid assay system
TW573125B (en) 2001-08-29 2004-01-21 Combinatorx Inc A screening system for identifying drug-drug interactions and methods of use thereof
US20060275829A1 (en) 2002-04-15 2006-12-07 Hammond David J Combinatorial library for proteomic investigations
US20060275753A1 (en) 2002-04-15 2006-12-07 Hammond David J Recovery of analytes using combinatorial libraries
AU2003299518A1 (en) * 2002-05-17 2004-05-13 Slanetz, Alfred E. Process for determining target function and identifying drug leads
CA2491969A1 (en) 2002-07-11 2004-01-22 The American National Red Cross Method for identifying individual active entities from complex mixtures
JP5072901B2 (ja) * 2003-02-24 2012-11-14 譲治 稲澤 薬剤耐性マーカーおよびその利用
WO2004080957A2 (en) * 2003-03-12 2004-09-23 Ramot At Tel Aviv University Ltd. Use of adnf polypeptides for treating anxiety and depression
KR101224235B1 (ko) * 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
CN1809383A (zh) * 2003-04-11 2006-07-26 免疫医疗公司 重组il－9抗体及其用途
WO2005037053A2 (en) * 2003-05-23 2005-04-28 Board Of Regents - The University Of Texas System High throughput screening of aptamer libraries for specific binding to proteins on viruses and other pathogens
CA2531571A1 (en) * 2003-07-08 2005-01-27 The Regents Of The University Of California Genetic marker of response to atypical antipsychotics and antidepressants and methods for use thereof
WO2005045430A1 (en) * 2003-10-08 2005-05-19 The Regents Of The University Of California Screening combinatorial bead libraries for cancer ligands
JP2006025069A (ja) * 2004-07-07 2006-01-26 Hitachi Ltd 機器制御装置及び電気機器
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
WO2006029411A2 (en) 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
JP2008520207A (ja) * 2004-11-16 2008-06-19 アヴィディア リサーチ インスティテュート タンパク質骨格およびその使用
US20060199206A1 (en) * 2005-03-01 2006-09-07 Hong Wang Method for identifying skin care composition-resistant skin-binding peptides
WO2006124644A2 (en) * 2005-05-12 2006-11-23 Board Of Regents, The University Of Texas System Protein and antibody profiling using small molecule microarrays
US8119572B2 (en) * 2005-10-24 2012-02-21 Wisconsin Alumni Research Foundation Methods for determining protein binding specificity using peptide libraries
US20070111322A1 (en) * 2005-11-15 2007-05-17 Lin-Cheng Yang Novel method of using inject printing for creating microarrays
CA2650706C (en) * 2006-05-25 2016-11-08 University Health Network Methods of diagnosing and treating rheumatoid arthritis and osteoarthritis
EP2140021B1 (en) * 2007-02-22 2012-01-11 Genentech, Inc. Methods for detecting inflammatory bowel disease
US20100266610A1 (en) * 2007-05-03 2010-10-21 Medimmune, Llc Auto-antibody markers of autoimmune disease
US8334239B2 (en) * 2007-07-10 2012-12-18 The Board Of Regents Of The University Of Texas System High affinity VEGF-receptor antagonists
TWM333876U (en) 2007-09-21 2008-06-11 Jer-Yuan Jang Device of auxiliary bathing tool
GB0724735D0 (en) * 2007-12-19 2008-01-30 Psynova Neurotech Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
WO2010014651A1 (en) * 2008-07-31 2010-02-04 The Brigham And Women's Hospital, Inc. Pharmacogenetic markers for susceptibility to drug-induced pancreatic toxicity
JP2010071744A (ja) * 2008-09-17 2010-04-02 Sekisui Chem Co Ltd 化合物のスクリーニング方法、並びに、スクリーニング用キット
AU2010253797B2 (en) 2009-05-29 2015-03-12 Opko Health, Inc. Peptoid ligands for isolation and treatment of autoimmune T-cells
MX2011012933A (es) * 2009-06-02 2012-03-07 Univ Texas Identificacion de moleculas pequeñas reconocidas por los anticuerpos en sujetos con enfermedades neurodegerativas.
JP2011004743A (ja) * 2009-06-26 2011-01-13 Dna Chip Research Inc 関節リウマチ患者におけるインフリキシマブ薬効の有効性を判別する方法
WO2011044253A1 (en) * 2009-10-06 2011-04-14 Wisconsin Alumni Research Foundation Metabolic biomarkers of drug-induced cardiotoxicity
WO2011047257A1 (en) * 2009-10-16 2011-04-21 The Board Of Regents Of The University Of Texas System Compositions and methods for producing cyclic peptoid libraries

Also Published As

Publication number Publication date
WO2012129423A3 (en) 2012-11-22
JP2014515739A (ja) 2014-07-03
TW201310033A (zh) 2013-03-01
KR20140027174A (ko) 2014-03-06
EP2689053B1 (en) 2018-11-14
EA201391382A1 (ru) 2014-09-30
WO2012129457A2 (en) 2012-09-27
CN103562444A (zh) 2014-02-05
CN103562444B (zh) 2017-08-25
JP2014510919A (ja) 2014-05-01
MX351228B (es) 2017-09-06
AU2012230880A1 (en) 2013-10-24
MX2013011000A (es) 2014-03-27
US20120269799A1 (en) 2012-10-25
EA032582B1 (ru) 2019-06-28
TWI630389B (zh) 2018-07-21
WO2012129423A2 (en) 2012-09-27
KR20140029411A (ko) 2014-03-10
BR112013024453A2 (pt) 2016-09-06
EA037648B1 (ru) 2021-04-27
JP6153921B2 (ja) 2017-06-28
CL2013002732A1 (es) 2014-04-04
CN103748270A (zh) 2014-04-23
EA201391378A1 (ru) 2014-09-30
AU2012230818B2 (en) 2016-12-08
AU2012230880B2 (en) 2017-04-13
JP6412798B2 (ja) 2018-10-24
CO6870002A2 (es) 2014-02-20
CL2013002731A1 (es) 2014-04-04
WO2012129457A3 (en) 2013-12-12
US20120270741A1 (en) 2012-10-25
AU2012230818A1 (en) 2013-10-24
EP2689053A4 (en) 2015-05-06
EP2688911B1 (en) 2017-08-02
CO6870029A2 (es) 2014-02-20
US9804168B2 (en) 2017-10-31
EP2688911A4 (en) 2015-08-26
TW201300591A (zh) 2013-01-01
CN103748270B (zh) 2018-04-24
BR112013024454A2 (pt) 2017-09-19
HK1197088A1 (en) 2015-01-02
EP2689053A2 (en) 2014-01-29
EP2688911A2 (en) 2014-01-29

Similar Documents

Publication Publication Date Title
MX2013010999A (es) Metodos de diagnostico y tratamiento utilizando una genoteca de ligandos.
WO2013192274A3 (en) Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
MX358517B (es) Métodos para determinar eficacia de fármacos usando proteínas asociadas a cereblon.
MX2013003077A (es) Diagnostico de cancer de mama.
BR112015012014A2 (pt) proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb)
BR112014031365A2 (pt) métodos de detectar doenças ou condições
EP2825676A4 (en) FAST DIAGNOSIS AND PERSONALIZED TREATMENTS FOR ACNE
MY174894A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
BR112016002000A2 (pt) Diagnóstico e terapia de câncer envolvendo células-tronco tumorais
EP2912438A4 (en) Health diagnostic systems and methods
BR112013010023A2 (pt) algoritimo aperfeiçoado para a detecção de diabetes
JP2012081319A5 (es)
EP3825419A3 (en) Diagnostic, prognostic and therapeutic uses of long noncoding rnas for heart disease and regenerative medicine
BR112013010952A2 (pt) sistemas de rmn e métodos para a detecção rápida de analisados
WO2012109466A3 (en) Long non-coding rna spry4-it1 as a diagnostic and therapeutic agent
EP2616818A4 (en) Red blood cell dynamics for diagnosis
EP3004394A4 (en) TESTS, METHODS AND KITS FOR ANALYZING SENSITIVITY AND RESISTANCE TO ANTICROBIAL AGENTS, PREDICTING THE PROGNOSIS OF A CANCER PATIENTS AND FOR PERSONALIZED TREATMENT STRATEGIES
WO2014158287A3 (en) A method for improving disease diagnosis using measured analytes
EA201490883A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛА К α-СИНУКЛЕИНУ ДЛЯ ДИАГНОСТИКИ ПОВЫШЕННОГО УРОВНЯ α-СИНУКЛЕИНА В МОЗГЕ
EP2888988A4 (en) PHOTODYNAMIC DIAGNOSTIC DEVICE WITH A COLLIMATOR
HK1213892A1 (zh) Tec家族激酶抑制剂疗法的伴随诊断
WO2015081283A3 (en) Long non-coding rna as a diagnostic and therapeutic agent
BR112016006556A2 (pt) arranjos detectáveis, sistemas para diagnóstico, e métodos para produzir e usar os mesmos
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
WO2014078468A3 (en) Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent

Legal Events

Date Code Title Description
FG Grant or registration